SeeMedX develops patented, non-invasive hemodynamic monitoring technology based on impedance principles. This system provides healthcare professionals with fast and accurate detection of changes in conditions like acute Congestive Heart Failure. The technology aims to improve patient care, enable timely treatment adjustments, and reduce overall healthcare costs.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing hemodynamics and detecting acute Congestive Heart Failure often involve invasive procedures or bulky equipment, leading to slower monitoring and potential patient discomfort. Existing non-invasive methods may lack the accuracy needed for timely and effective treatment adjustments.
Solution
SeeMedX offers smart, non-invasive monitors that utilize bioimpedance technology to accurately assess a patient's hemodynamics and detect acute Congestive Heart Failure. The technology measures impedance, the resistance to the flow of electrical current, to determine fluid volume and cardiac function. By monitoring changes in thoracic fluid, the device enables faster and more accurate detection of changes needed for proper treatment adjustment. This approach provides a pain-free monitoring experience, improving patient care and potentially reducing healthcare costs.
Target Audience
The primary users are healthcare professionals, including doctors, nurses, and technicians, who need accurate and timely hemodynamic data for patients at risk of or suffering from Congestive Heart Failure.
Features
- Non-invasive hemodynamic monitoring using patented bioimpedance methodology.
- Accurate assessment of contractility, cardiac output, and fluid volume.
- Telehealth capabilities for remote patient monitoring.